Mode of Action (MoA) and Phase III Data
Learn about the MoA of Vyxeos Liposomal, as well as the Phase III data in high-risk* acute myeloid leukaemia (AML) patients.
Prescribing information can be found at the top of this page. Adverse event reporting is available at the bottom of this page.
Topics: Safety Vyxeos Liposomal Data